N-[4-(5-amino-1,2,4-thiadiazol-3-yl)phenyl]methanesulfonamide | 1101173-88-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[4-(5-amino-1,2,4-thiadiazol-3-yl)phenyl]methanesulfonamide
• CAS: 1101173-88-9
• 化学式: C₉H₁₀N₄O₂S₂
• 分子量: 270.336
• InChiKey: PDGWPTMIRMYFGX-UHFFFAOYSA-N

物化性质

• 沸点：
  496.2±55.0 °C(Predicted)
• 密度：
  1.558±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  135
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (3,3-diphenyl-propyl)-(2-morpholin-4-yl-ethyl)-amine 、 N-[4-(5-amino-1,2,4-thiadiazol-3-yl)phenyl]methanesulfonamide 、 N,N'-羰基二咪唑 在 4-二甲氨基吡啶 作用下， 反应 60.0h， 生成 1-(3,3-Diphenylpropyl)-3-[3-[4-(methanesulfonamido)phenyl]-1,2,4-thiadiazol-5-yl]-1-(2-morpholin-4-ylethyl)urea
  参考文献：
  名称：

  Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism

  摘要：

  A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essential to finding a compound suitable for oral dosing. Calcimimetic 18 exhibited excellent in vivo potency in a 5/6 nephrectomized rat model and cross-species pharmacokinetics. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.10.050
• 作为产物：
  描述：

  C₁₄H₁₈N₄O₄S₂ 在 苯甲醚 、 三氟乙酸 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.5h， 以91%的产率得到N-[4-(5-amino-1,2,4-thiadiazol-3-yl)phenyl]methanesulfonamide
  参考文献：
  名称：

  从常见的前体轻松合成取代的5-氨基-和3-氨基-1,2,4-噻二唑

  摘要：

  已经实现了从常见的前体开始合成取代的5-氨基-和3-氨基-1,2,4-噻二唑的新颖方法。通过钯催化的Suzuki-Miyaura偶联进行的衍生化作用可以围绕该药学相关核心快速制备类似物。FMO计算可合理化所观察到的在氯上偶合的化学选择性。

  DOI：

  10.1021/ol902371y

文献信息

• Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
  申请人：Deprez Pierre

  公开号：US20090054463A1

  公开（公告）日：2009-02-26

  The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.

  本发明一般涉及代表式I的化合物、包含它们的药物组合物以及治疗与钙感受受体功能相关的疾病或障碍的方法。本发明还涉及制备此类化合物的方法以及在这些过程中有用的中间体。
• DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR
  申请人：Amgen Inc.

  公开号：EP2176247A2

  公开（公告）日：2010-04-21
• US8324396B2
  申请人：——

  公开号：US8324396B2

  公开（公告）日：2012-12-04
• [EN] DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR<br/>[FR] DÉRIVÉS DE L'URÉE ET DE DIAMINES ASSOCIÉES, LEURS PROCÉDÉS DE FABRICATION, ET LEURS UTILISATIONS
  申请人：AMGEN INC

  公开号：WO2009009122A2

  公开（公告）日：2009-01-15

  The present invention relates generally to compounds represented in Formula (I), pharamaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.
• Facile Synthesis of Substituted 5-Amino- and 3-Amino-1,2,4-Thiadiazoles from a Common Precursor
  作者：Paul M. Wehn、Paul E. Harrington、John E. Eksterowicz

  DOI：10.1021/ol902371y

  日期：2009.12.17

  A novel approach to the synthesis of substituted 5-amino- and 3-amino-1,2,4-thiadiazoles beginning from a common precursor has been achieved. Derivatization by palladium-catalyzed Suzuki−Miyaura coupling enables the rapid preparation of analogs around this pharmaceutically relevant core. FMO calculations rationalize the observed chemoselectivity for coupling at chlorine.

  已经实现了从常见的前体开始合成取代的5-氨基-和3-氨基-1,2,4-噻二唑的新颖方法。通过钯催化的Suzuki-Miyaura偶联进行的衍生化作用可以围绕该药学相关核心快速制备类似物。FMO计算可合理化所观察到的在氯上偶合的化学选择性。